Designing Earlier Disease Detection

Analyze the broader opportunity and tradeoffs of using blood-based biomarkers, genetic signals, and other minimally invasive tests to detect diseases earlier. Compare the potential benefits for patients, clinicians, insurers, and public health systems with the risks of false positives, overdiagnosis, privacy concerns, and unequal access. Then propose a realistic roadmap for how a healthcare system could adopt earlier-detection tools responsibly.